48
Participants
Start Date
August 3, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
BH011
BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
RECRUITING
Peking University First Hospital, Beijing
COMPLETED
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
The Second Hospital of Tianjin Medical University, Tianjin
COMPLETED
The First Affiliated Hospital of Xiamen University, Xiamen
COMPLETED
Hunan Cancer Hospital, Changsha
Zhuhai Beihai Biotech Co., Ltd
INDUSTRY